Iterum Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Orlynvah’s U.S. launch generated $0.4M in Q3 sales, with over 280 prescriptions and growing physician adoption. 2026 revenue is guided at $5–$15M, but further capital is needed to sustain commercialization beyond Q2 2026. Coverage now reaches 16% of insured lives.
-
ORLYNVAH is launching ahead of schedule in August 2025, targeting a large unmet need in the U.S. urinary tract infection market, with initial focus on high-value territories and strong patent protection. Q2 2025 saw increased expenses due to pre-commercialization, and cash is expected to fund operations into 2026.
-
Extended Pfizer milestone payment eases financial pressure and supports Orlynvah's U.S. launch, now targeted for Q4 2025 with Eversana. Strong market need, robust IP protection, and phased launch strategy position Orlynvah for success in a large, underserved market.
-
Q1 2025 saw reduced operating expenses and net loss, with a strong cash position supporting the planned Q4 launch of Orlynvah. Strategic alternatives are being explored, but urgency remains to commercialize Orlynvah amid new competitor approvals and a large addressable market.
Fiscal Year 2024
-
FDA approval of Orlinva marked a pivotal year, with strong clinical results and a focus on strategic options for commercialization. Operating expenses and net loss decreased significantly, and cash is expected to fund operations into the second half of 2025.
-
FDA approval of Orlynvah provides a new oral treatment for uUTI amid rising resistance rates, with 10 years of exclusivity and strong patent protection. Operating expenses fell sharply post-trial, and cash runway extends into 2025 as strategic partnership efforts continue.
-
FDA approved Orlynvah as the first oral penem antibiotic for uncomplicated UTIs in adult women with limited treatment options, addressing a major unmet need amid rising resistance rates. The product offers a favorable safety profile and targets a large, underserved market.
-
Sulopenem is nearing a key FDA decision as the first oral penem for uncomplicated UTIs, targeting a large, high-risk patient population facing rising antibiotic resistance. The company is focused on securing a commercial partner and maximizing value post-approval.
-
Q2 2024 saw a significant reduction in operating expenses and net loss, with $5.8M raised in a rights offering to fund operations into 2025. Key milestones include an FDA advisory committee meeting and a PDUFA date for oral sulopenem, which could become the first oral penem in the U.S.